TherapeuticsMD, Inc.

The momentum for this stock is not very good. TherapeuticsMD, Inc. is not a good value stock. TherapeuticsMD, Inc. is not very popular among insiders. TherapeuticsMD, Inc. is a mediocre stock to choose.
Log in to see more information.
TherapeuticsMD, Inc. operates as a healthcare company, which focuses on developing and commercializi...
TXMD Fundamental Data by TradingView

News

TherapeuticsMD (NASDAQ:TXMD) Research Coverage Started at StockNews.com
TherapeuticsMD (NASDAQ:TXMD) Research Coverage Started at StockNews.com

Ticker Report Equities research analysts at StockNews.com initiated coverage on shares of TherapeuticsMD (NASDAQ:TXMD - Get Free Report) in a report issued on Tuesday. The firm set a "hold" rating on the stock...\n more…

TherapeuticsMD (NASDAQ:TXMD) Receives New Coverage from Analysts at StockNews.com
TherapeuticsMD (NASDAQ:TXMD) Receives New Coverage from Analysts at StockNews.com

Zolmax StockNews.com assumed coverage on shares of TherapeuticsMD (NASDAQ:TXMD - Free Report) in a research report sent to investors on Wednesday morning. The brokerage issued a hold rating on the...\n more…

TherapeuticsMD (NASDAQ:TXMD) Receives New Coverage from Analysts at StockNews.com
TherapeuticsMD (NASDAQ:TXMD) Receives New Coverage from Analysts at StockNews.com

Ticker Report Equities research analysts at StockNews.com assumed coverage on shares of TherapeuticsMD (NASDAQ:TXMD - Get Free Report) in a report issued on Wednesday. The brokerage set a "hold" rating on the...\n more…

TherapeuticsMD (NASDAQ:TXMD) Now Covered by StockNews.com
TherapeuticsMD (NASDAQ:TXMD) Now Covered by StockNews.com

Ticker Report StockNews.com began coverage on shares of TherapeuticsMD (NASDAQ:TXMD - Free Report) in a research note released on Thursday morning. The brokerage issued a hold rating on the stock. TherapeuticsMD...\n more…

TherapeuticsMD (NASDAQ:TXMD) Receives New Coverage from Analysts at StockNews.com
TherapeuticsMD (NASDAQ:TXMD) Receives New Coverage from Analysts at StockNews.com

Zolmax StockNews.com began coverage on shares of TherapeuticsMD (NASDAQ:TXMD - Free Report) in a research note released on Friday morning. The firm issued a hold rating on the stock.\nTherapeuticsMD Stock...\n more…

TherapeuticsMD And 2 Other Stocks Under $2 Executives Are Buying
TherapeuticsMD And 2 Other Stocks Under $2 Executives Are Buying

Benzinga The Dow Jones index closed higher by more than 450 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.\n more…